ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
26/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseARCT / S&P -12.95% / 15.20% |
LoseARCT / S&P -75.95% / 15.00% |
LoseARCT / S&P 49.33% / 50.40% |
| 2026-Q11/3 |
WinARCT / S&P 25.94% / -4.33% |
LoseARCT / S&P -61.92% / 11.30% |
LoseARCT / S&P 11.86% / 27.70% |
| 2025-Q40/3 |
LoseARCT / S&P -66.74% / 2.65% |
LoseARCT / S&P -46.14% / 9.00% |
LoseARCT / S&P -20.27% / 13.40% |
| 2025-Q31/3 |
WinARCT / S&P 41.66% / 8.12% |
LoseARCT / S&P -39.15% / 4.61% |
LoseARCT / S&P 5.13% / 13.45% |
| 2025-Q21/3 |
WinARCT / S&P 22.85% / 10.94% |
LoseARCT / S&P -25.47% / 4.83% |
LoseARCT / S&P -17.10% / 10.63% |
| 2025-Q11/3 |
LoseARCT / S&P -37.60% / -4.27% |
WinARCT / S&P 15.38% / 4.98% |
LoseARCT / S&P -37.22% / 10.57% |
| 2024-Q41/3 |
LoseARCT / S&P -26.88% / 2.41% |
LoseARCT / S&P -8.69% / 5.25% |
WinARCT / S&P 159.48% / 6.15% |
| 2024-Q30/3 |
LoseARCT / S&P -4.68% / 5.89% |
LoseARCT / S&P -45.85% / 5.89% |
LoseARCT / S&P -162.90% / 6.11% |
| 2024-Q20/3 |
LoseARCT / S&P -27.89% / 4.28% |
LoseARCT / S&P -38.04% / 5.38% |
LoseARCT / S&P -189.67% / 5.12% |
| 2024-Q10/3 |
LoseARCT / S&P 7.10% / 10.56% |
LoseARCT / S&P -55.69% / 5.71% |
LoseARCT / S&P -196.87% / 5.59% |
| 2023-Q41/3 |
WinARCT / S&P 23.41% / 11.69% |
LoseARCT / S&P -19.03% / 6.81% |
LoseARCT / S&P -431.43% / 7.78% |
| 2023-Q31/3 |
LoseARCT / S&P -10.91% / -3.27% |
WinARCT / S&P 475.22% / 7.52% |
LoseARCT / S&P -166.91% / -5.03% |
| 2023-Q22/3 |
WinARCT / S&P 19.65% / 8.74% |
WinARCT / S&P 551.91% / 9.50% |
LoseARCT / S&P -147.77% / -8.57% |
| 2023-Q12/3 |
WinARCT / S&P 41.33% / 7.50% |
WinARCT / S&P 1715.97% / 10.77% |
LoseARCT / S&P -155.25% / -15.69% |
| 2022-Q42/3 |
WinARCT / S&P 14.44% / 7.56% |
WinARCT / S&P 1566.79% / 11.88% |
LoseARCT / S&P ARCT unavailable / -17.99% |
| 2022-Q31/3 |
LoseARCT / S&P -5.84% / -4.88% |
WinARCT / S&P 485.03% / 13.47% |
LoseARCT / S&P ARCT unavailable / -1.41% |
| 2022-Q21/3 |
LoseARCT / S&P -41.62% / -16.10% |
WinARCT / S&P 366.35% / 13.71% |
LoseARCT / S&P ARCT unavailable / 11.04% |
| 2022-Q11/3 |
LoseARCT / S&P -27.15% / -4.60% |
WinARCT / S&P 71.57% / 15.97% |
LoseARCT / S&P ARCT unavailable / 42.23% |
| 2021-Q41/3 |
LoseARCT / S&P -22.54% / 11.03% |
WinARCT / S&P 29.56% / 15.00% |
LoseARCT / S&P ARCT unavailable / 96.40% |
| 2021-Q31/3 |
WinARCT / S&P 41.19% / 0.58% |
LoseARCT / S&P -14.28% / 10.77% |
LoseARCT / S&P ARCT unavailable / 69.42% |
| 2021-Q20/3 |
LoseARCT / S&P -18.06% / 8.55% |
LoseARCT / S&P -22.70% / 6.58% |
LoseARCT / S&P ARCT unavailable / 51.81% |
| 2021-Q10/3 |
LoseARCT / S&P -4.79% / 6.17% |
LoseARCT / S&P -52.74% / -1.06% |
LoseARCT / S&P ARCT unavailable / 7.39% |
| 2020-Q40/3 |
LoseARCT / S&P 1.12% / 12.15% |
LoseARCT / S&P -54.12% / -3.72% |
LoseARCT / S&P ARCT unavailable / -33.42% |
| 2020-Q30/3 |
LoseARCT / S&P -8.22% / 8.93% |
LoseARCT / S&P -59.57% / -2.04% |
LoseARCT / S&P ARCT unavailable / -27.10% |
| 2020-Q21/3 |
WinARCT / S&P 243.93% / 20.54% |
LoseARCT / S&P -55.87% / -0.46% |
LoseARCT / S&P ARCT unavailable / -27.11% |
| 2020-Q12/3 |
WinARCT / S&P 25.02% / -19.60% |
WinARCT / S&P 7.61% / 3.47% |
LoseARCT / S&P ARCT unavailable / -14.75% |
| 2019-Q40/3 |
LoseARCT / S&P 5.84% / 9.07% |
LoseARCT / S&P ARCT unavailable / 5.36% |
LoseARCT / S&P ARCT unavailable / 2.99% |
| 2019-Q31/3 |
WinARCT / S&P 8.79% / 1.70% |
LoseARCT / S&P ARCT unavailable / 5.02% |
LoseARCT / S&P ARCT unavailable / 0.21% |
| 2019-Q21/3 |
WinARCT / S&P 38.21% / 4.30% |
LoseARCT / S&P ARCT unavailable / 6.64% |
LoseARCT / S&P ARCT unavailable / 8.65% |
| 2019-Q11/3 |
WinARCT / S&P 50.77% / 13.65% |
LoseARCT / S&P ARCT unavailable / 8.12% |
LoseARCT / S&P ARCT unavailable / 14.29% |
| 2018-Q40/3 |
LoseARCT / S&P -48.76% / -13.52% |
LoseARCT / S&P ARCT unavailable / 9.05% |
LoseARCT / S&P ARCT unavailable / 18.23% |
| 2018-Q30/3 |
LoseARCT / S&P 4.25% / 7.71% |
LoseARCT / S&P ARCT unavailable / 10.21% |
LoseARCT / S&P ARCT unavailable / 19.06% |
| 2018-Q21/3 |
WinARCT / S&P 54.18% / 3.43% |
LoseARCT / S&P ARCT unavailable / 9.03% |
LoseARCT / S&P ARCT unavailable / 14.46% |
| 2018-Q10/3 |
LoseARCT / S&P -30.82% / -0.76% |
LoseARCT / S&P ARCT unavailable / 7.68% |
LoseARCT / S&P ARCT unavailable / 12.46% |
| 2017-Q41/3 |
WinARCT / S&P 12.45% / 6.64% |
LoseARCT / S&P ARCT unavailable / 7.03% |
LoseARCT / S&P ARCT unavailable / 13.82% |
| 2017-Q30/3 |
LoseARCT / S&P -9.82% / 4.48% |
LoseARCT / S&P ARCT unavailable / 5.68% |
LoseARCT / S&P ARCT unavailable / 17.57% |
| 2017-Q20/3 |
LoseARCT / S&P -1.75% / 3.09% |
LoseARCT / S&P ARCT unavailable / 4.83% |
LoseARCT / S&P ARCT unavailable / 17.74% |
| 2017-Q10/3 |
LoseARCT / S&P -45.71% / 6.07% |
LoseARCT / S&P ARCT unavailable / 3.67% |
LoseARCT / S&P ARCT unavailable / 13.32% |
| 2016-Q40/3 |
LoseARCT / S&P -14.98% / 3.82% |
LoseARCT / S&P ARCT unavailable / 2.09% |
LoseARCT / S&P ARCT unavailable / 7.05% |
| 2016-Q30/3 |
LoseARCT / S&P -44.99% / 3.85% |
LoseARCT / S&P ARCT unavailable / 0.20% |
LoseARCT / S&P ARCT unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ARCT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -4.94% | 20.78% |
| Annualized return | -4.94% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ARCT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -71.33% | 83.14% |
| Annualized return | -22.11% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ARCT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -51.27% | 319.30% |
| Annualized return | -6.94% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |